Rethinking Patient Representation In Breast Cancer Trials For Better Outcomes

By Claudia Marques Vasconcelos, M.D., Senior Medical Director and Therapeutic Area Lead, Breast/Gynecologic Cancer

As breast cancer research advances toward greater precision and global relevance, broad patient representation in clinical trials remains critical to generating clinically relevant, generalizable data. Inclusive trial populations are critical for scientific validity, regulatory confidence, and long‑term commercial success. Narrow enrollment criteria can limit generalizability and fail to reflect real‑world patients, including older adults, men with breast cancer, individuals with comorbidities, rural populations, and patients with varied performance status, and can slow enrollment and limit trial efficiency.

This article examines the scientific, regulatory, and business rationale for designing breast cancer trials that reflect real-world populations most likely to receive treatment. Broad inclusion improves understanding of treatment safety, efficacy, and dosing across subgroups and supports biomarker‑driven development. Regulatory agencies increasingly expect evidence generated from representative populations, while health technology assessment bodies value data that reflects routine clinical practice.

The article concludes with practical strategies for sponsors, including eligibility optimization, targeted site selection, community partnerships, and decentralized or hybrid trial models, to enable sustainable patient representation and reduce downstream regulatory and commercial risk.